Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

KIF4A knockdown suppresses ovarian cancer cell proliferation and induces apoptosis by downregulating BUB1 expression.

Tytuł:
KIF4A knockdown suppresses ovarian cancer cell proliferation and induces apoptosis by downregulating BUB1 expression.
Autorzy:
Jin W; Reproductive Medicine Center, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, P.R. China.
Ye L; Department of Intensive Care Unit, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, P.R. China.
Źródło:
Molecular medicine reports [Mol Med Rep] 2021 Jul; Vol. 24 (1). Date of Electronic Publication: 2021 May 20.
Typ publikacji:
Journal Article
Język:
English
Imprint Name(s):
Original Publication: Athens, Greece : D. A. Spandidos
MeSH Terms:
Apoptosis/*drug effects
Cell Proliferation/*drug effects
Kinesins/*genetics
Kinesins/*metabolism
Ovarian Neoplasms/*genetics
Ovarian Neoplasms/*metabolism
Protein Serine-Threonine Kinases/*genetics
Protein Serine-Threonine Kinases/*metabolism
Cell Cycle ; Cell Line, Tumor ; Cell Movement ; Cell Survival ; Down-Regulation ; Female ; Gene Expression Regulation, Neoplastic ; Gene Knockdown Techniques ; Humans ; Kinesins/pharmacology ; Wound Healing
References:
J Ovarian Res. 2019 Apr 22;12(1):35. (PMID: 31010415)
Biomed Pharmacother. 2019 Jan;109:726-733. (PMID: 30551525)
Nucleic Acids Res. 2003 Jan 1;31(1):258-61. (PMID: 12519996)
Sci Rep. 2017 Jun 23;7(1):4148. (PMID: 28646197)
Ecancermedicalscience. 2014 Sep 25;8:465. (PMID: 25371706)
Mol Med Rep. 2021 Jan;23(1):. (PMID: 33179082)
EMBO J. 2004 Aug 18;23(16):3237-48. (PMID: 15297875)
Nat Rev Cancer. 2012 Jul 24;12(8):527-39. (PMID: 22825217)
J Ovarian Res. 2019 Nov 18;12(1):113. (PMID: 31739800)
Cell Death Dis. 2018 Apr 30;9(5):477. (PMID: 29706624)
J Ovarian Res. 2020 Jan 27;13(1):10. (PMID: 31987036)
Methods. 2001 Dec;25(4):402-8. (PMID: 11846609)
Oncotarget. 2017 Jul 18;8(44):76329-76339. (PMID: 29100315)
Onco Targets Ther. 2016 Apr 15;9:2211-20. (PMID: 27143916)
Gynecol Oncol. 2012 Oct;127(1):75-82. (PMID: 22750127)
J Immunother Cancer. 2019 Feb 1;7(1):27. (PMID: 30709424)
Semin Oncol Nurs. 2019 Apr;35(2):151-156. (PMID: 30867104)
Pharmacology. 2017;100(5-6):269-282. (PMID: 28810242)
Oncol Lett. 2018 May;15(5):7941-7947. (PMID: 29725481)
Trends Biochem Sci. 2011 Mar;36(3):141-50. (PMID: 20888775)
Onco Targets Ther. 2018 Aug 10;11:4755-4768. (PMID: 30127624)
Curr Biol. 2011 May 24;21(10):815-24. (PMID: 21565503)
Cytogenet Cell Genet. 2000;88(1-2):41-2. (PMID: 10773663)
J Cell Biochem. 2019 Jun;120(6):9522-9531. (PMID: 30506958)
J Cell Biol. 2004 Aug 30;166(5):613-20. (PMID: 15326200)
Best Pract Res Clin Obstet Gynaecol. 2017 May;41:3-14. (PMID: 27743768)
Semin Surg Oncol. 2000 Jul-Aug;19(1):3-10. (PMID: 10883018)
Contributed Indexing:
Keywords: apoptosis; budding uninhibited by benzimidazoles 1; kinesin family member 4A; ovarian cancer; proliferation
Substance Nomenclature:
EC 2.7.11.1 (BUB1 protein, human)
EC 2.7.11.1 (Protein Serine-Threonine Kinases)
EC 3.6.1.- (KIF4A protein, human)
EC 3.6.4.4 (Kinesins)
Entry Date(s):
Date Created: 20210520 Date Completed: 20211108 Latest Revision: 20211204
Update Code:
20240104
PubMed Central ID:
PMC8160479
DOI:
10.3892/mmr.2021.12155
PMID:
34013367
Czasopismo naukowe
Ovarian cancer is one of the most common lethal gynecological malignancies worldwide. Abnormal kinesin family member 4A (KIF4A) expression has been implicated in ovarian cancer progression; however, the potential mechanism underlying KIF4A in ovarian cancer is not completely understood. The present study aimed to clarify the molecular basis of KIF4A in ovarian cancer. KIF4A and budding uninhibited by benzimidazoles 1 (BUB1) expression levels were detected via reverse transcription-quantitative PCR and western blotting. Cell Counting Kit-8, colony formation, wound healing, TUNEL and flow cytometry assays were performed to assess cell proliferation, migration, apoptosis and cell cycle distribution, respectively. Ki67 expression levels were detected by conducting immunofluorescence assays. The expression levels of migration- and apoptosis-related proteins were measured via western blotting. A co-immunoprecipitation assay was conducted to determine the association between KIF4A and BUB1. The results demonstrated that KIF4A was expressed at significantly higher levels in ovarian cancer cell lines compared with IOSE-80 cells. Compared with the short hairpin RNA-negative control group, KIF4A knockdown significantly inhibited cell viability, colony formation and migration, and markedly induced cell apoptosis. The results indicated that KIF4A could bind to BUB1 and regulate BUB1 expression. BUB1 overexpression weakened KIF4A knockdown-mediated effects on cell viability, colony formation, migration and apoptosis. Overall, the present study demonstrated that KIF4A knockdown suppressed ovarian cancer progression by regulating BUB1, and suggested the potential value of KIF4A and BUB1 as therapeutic targets for ovarian cancer.
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies